NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Electra Therapeutics

Electra Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://electra-therapeutics.com/

Last Round

Series C

Oct 22, 2025

Est. Valuation

$479M

Total Funding Raised

$267M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Electra Therapeutics is a biotechnology company developing antibody therapies that target signal regulatory proteins to treat immunological diseases and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologymonoclonal antibodyclinical-stage biotechSIRP alphaT-cell malignanciesimmune-mediated diseasesdrug developmentclinical trialsbiopharmaimmunotherapycheckpoint inhibitortherapeutic pipelineoncologybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Electra Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Electra Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Electra Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series COct 22, 2025
Series BFeb 16, 2022

Key People

Founding team and executive leadership

Kathy Dong

President And CEO

Executive Team

Electra Therapeutics Investors

Notable investors and investment history

Electra Therapeutics investors
InvestorRounds
Redmile GroupSeries B, Series C
RA Capital ManagementSeries C, Series B
New Leaf Venture PartnersSeries C, Series B
EQT Life SciencesSeries C
Westlake Village BioPartnersSeries C, Series B
Cowen Private InvestmentsSeries B
Cormorant Asset ManagementSeries C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 12, 2026

    Presenting at the 44th annual J.P. Morgan Healthcare Conference on January 12, 2026.

  • Dec 2, 2025

    Presented SURPASS trial design for ELA026 at ASH 2025.

Electra Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Electra Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Electra Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range43
Year Founded2018
Last FundingOct 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.